VeriSeq NIPT Solution v2 is a next-generation sequencing based method to noninvasive prenatal testing
Illumina's VeriSeq NIPT Solution v2. (Credit: Business Wire)
Illumina has collaborated with Next Generation Genomic (NGG Thailand) to introduce an automated in-lab IVD solution called VeriSeq NIPT Solution v2 in Thailand.
VeriSeq NIPT Solution v2 is a CE-IVD approved and next-generation sequencing (NGS)-based method to noninvasive prenatal testing (NIPT).
The automated in-lab IVD solution will enable NGG Thailand to introduce the Qualifi Prenatal Test. It will also become the first laboratory in South East Asia to offer enhanced insights into the health of pregnancy compared to standard NIPT offerings.
The test uses Illumina’s VeriSeq NIPT Solution v2 to provide a comprehensive view of the fetal genome compared to other CE-IVD NIPT products.
It will help healthcare providers to provide expectant parents with informed, timely and personalised management options.
The VeriSeq NIPT Solution will allow NGG Thailand’s Qualifi Prenatal Test to deliver precise information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw.
With a whole-genome sequencing (WGS) approach to NIPT, the noninvasive test expands prenatal screening beyond the three most common aneuploidies of chromosomes 21, 18 and 13 to all rare autosomal aneuploidies (RAAs), sex chromosome aneuploidies (SCAs), and large partial duplications and deletions.
Illumina Asia Pacific and Japan general manager and vice president Gretchen Weightman said: “Illumina’s comprehensive technologies, coupled with NGG Thailand’s expertise, will enable healthcare providers and expectant parents to unlock the most critical information possible today.”
The CE-IVD VeriSeq NIPT Solution v2 is currently registered for use in Thailand, Vietnam, Singapore, South Korea, Australia, New Zealand, Israel, South Africa and across most countries in Europe.
In September last year, Illumina agreed to acquire US-based healthcare company GRAIL for cash and stock consideration of $8bn.